Literature DB >> 18775122

Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?

Domenic A Sica1.   

Abstract

Examination of the large-scale drug-versus-drug trials suggests that the initial drug choice is of token importance and that better blood pressure control is the primary determinant of superior outcomes. In pooled analyses, the achieved blood pressure is similar for older and less expensive drugs, such as thiazide-type diuretics, and for newer and more costly agents, such as angiotensin-converting enzyme inhibitors, -angiotensin-receptor blockers, and calcium-channel blockers. If blood pressure--independent differences favoring one antihypertensive drug class over another truly exist, they have been singularly difficult to uncover with any consistency. Considering that multidrug therapy is required in the majority of patients with hypertension, the debate as to which drug class is best to start with is moot, in that the clinician is now more called upon to decide the best combinations of drugs and not the best monotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18775122     DOI: 10.1007/s11906-008-0077-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  40 in total

Review 1.  Pleiotropic effects of statins and their clinical significance.

Authors:  J C LaRosa
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.

Authors:  Scott D Solomon; Madeline M Rice; Kathleen A Jablonski; Powell Jose; Michael Domanski; Marc Sabatine; Bernard J Gersh; Jean Rouleau; Marc A Pfeffer; Eugene Braunwald
Journal:  Circulation       Date:  2006-06-26       Impact factor: 29.690

Review 4.  Class effects of angiotensin-converting enzyme inhibitors.

Authors:  D A Sica
Journal:  Am J Manag Care       Date:  2000-02       Impact factor: 2.229

Review 5.  Clinical trials in nephrology: success or failure.

Authors:  Jose A Garcia-Donaire; Julian Segura; Luis M Ruilope
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-03       Impact factor: 2.894

6.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

Authors:  Jan A Staessen; Ji-Guang Wang; Lutgarde Thijs
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

7.  Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?

Authors:  Louise Pilote; Michal Abrahamowicz; Eric Rodrigues; Mark J Eisenberg; Elham Rahme
Journal:  Ann Intern Med       Date:  2004-07-20       Impact factor: 25.391

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.

Authors:  F Turnbull; B Neal; M Pfeffer; J Kostis; C Algert; M Woodward; J Chalmers; A Zanchetti; S MacMahon
Journal:  J Hypertens       Date:  2007-05       Impact factor: 4.844

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  2 in total

1.  Are there pleiotropic effects of antihypertensive medications or is it all about the blood pressure in the patient with diabetes and hypertension?

Authors:  Domenic Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04       Impact factor: 3.738

Review 2.  Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

Authors:  Thomas Unger; Ludovit Paulis; Domenic A Sica
Journal:  Eur Heart J       Date:  2011-09-27       Impact factor: 29.983

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.